Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials • Medical Devices & Mechanical Engineering
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Children`S Medical Center Corporation has 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 5 distinct examiners, meaning no two pending cases are currently being reviewed by the same person. The portfolio is active in 4 distinct art units, indicating a relatively concentrated technical focus.
NEAL, TIMOTHY JAY is the busiest examiner, responsible for 1 pending office action. With 5 distinct examiners involved, the company faces a diverse set of perspectives during prosecution. The presence of 4 distinct art units suggests that while the examiners differ, the technical subject matter remains largely within a few specialized groups. This distribution requires managing 5 distinct examiner relationships while navigating the technical nuances of 4 distinct art units.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| §102 only | 1 (20%) |
| Double-patenting only | 2 (40%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NEAL, TIMOTHY JAY | 1 | 77.8% | +13.5% |
| MUI, CHRISTINE T | 1 | 78.3% | +19.9% |
| SIPPEL, RACHEL T | 1 | 52.4% | +58.3% |
| BEHARRY, ZANNA MARIA | 1 | 24.7% | +56.4% |
| COUGHLIN, MATTHEW P | 1 | 71.3% | +12.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17430822 | Treating Heart Failure | BEHARRY, ZANNA MARIA | 100d overdue |
| 17273937 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | COUGHLIN, MATTHEW P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17430822 | Treating Heart Failure | BEHARRY, ZANNA MARIA | 100d overdue |
| 17603646 | AEROSOLIZED COMPOSITIONS COMPRISING MITOCHONDRIA AND METHODS OF USE THEREOF | SIPPEL, RACHEL T | 33d |
| 19081947 | INTERVENTIONAL DEVICE WITH ADJUSTABLE CONFIGURATION | NEAL, TIMOTHY JAY | — |
| 18036020 | METHODS AND COMPOSITIONS FOR TAUOPATHY DIAGNOSIS AND TREATMENT | MUI, CHRISTINE T | — |
| 17273937 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | COUGHLIN, MATTHEW P | — |
| Art Unit | Apps |
|---|---|
| 1797 | 1 |
| 3785 | 1 |
| 1632 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19081947 | INTERVENTIONAL DEVICE WITH ADJUSTABLE CONFIGURATION | NEAL, TIMOTHY JAY | — | DP | Non-Final OA | — | Pending | Mar 17, 2025 |
| 18036020 | METHODS AND COMPOSITIONS FOR TAUOPATHY DIAGNOSIS AND TREATMENT | MUI, CHRISTINE T | 1797 | §102Other | Non-Final OA | — | Pending | May 09, 2023 |
| 17603646 | AEROSOLIZED COMPOSITIONS COMPRISING MITOCHONDRIA AND METHODS OF USE THEREOF | SIPPEL, RACHEL T | 3785 | §103 | Final Rejection | 33d | Pending | Oct 14, 2021 |
| 17430822 | Treating Heart Failure | BEHARRY, ZANNA MARIA | 1632 | DP | Final Rejection | 100d overdue | Pending | Aug 13, 2021 |
| 17273937 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | COUGHLIN, MATTHEW P | 1626 | §103§112 | Final Rejection | — | Pending | Mar 05, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial